PortalPublikationenInterleukin-2 receptor antagonist induction in modern immuno...

Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.

Standard

Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. / Vincenti, Flavio; de Andrés, Amado; Becker, Thomas; Choukroun, Gabriel; Cole, Edward; González-Posada, José M; Kumar, Mysore A; Moore, Richard; Nadalin, Silvio; Nashan, Björn; Rostaing, Lionel; Saito, Kazuhide; Yoshimura, Norio.

in: TRANSPL INT, Jahrgang 19, Nr. 6, 6, 2006, S. 446-457.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Vincenti, F, de Andrés, A, Becker, T, Choukroun, G, Cole, E, González-Posada, JM, Kumar, MA, Moore, R, Nadalin, S, Nashan, B, Rostaing, L, Saito, K & Yoshimura, N 2006, 'Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.', TRANSPL INT, Jg. 19, Nr. 6, 6, S. 446-457. <http://www.ncbi.nlm.nih.gov/pubmed/16771865?dopt=Citation>

APA

Vincenti, F., de Andrés, A., Becker, T., Choukroun, G., Cole, E., González-Posada, J. M., Kumar, M. A., Moore, R., Nadalin, S., Nashan, B., Rostaing, L., Saito, K., & Yoshimura, N. (2006). Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. TRANSPL INT, 19(6), 446-457. [6]. http://www.ncbi.nlm.nih.gov/pubmed/16771865?dopt=Citation

Vancouver

Vincenti F, de Andrés A, Becker T, Choukroun G, Cole E, González-Posada JM et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. TRANSPL INT. 2006;19(6):446-457. 6.

Bibtex

@article{355139b6e1644f9ea47068ad026f220d,
title = "Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.",
abstract = "Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.",
author = "Flavio Vincenti and {de Andr{\'e}s}, Amado and Thomas Becker and Gabriel Choukroun and Edward Cole and Gonz{\'a}lez-Posada, {Jos{\'e} M} and Kumar, {Mysore A} and Richard Moore and Silvio Nadalin and Bj{\"o}rn Nashan and Lionel Rostaing and Kazuhide Saito and Norio Yoshimura",
year = "2006",
language = "Deutsch",
volume = "19",
pages = "446--457",
journal = "TRANSPL INT",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.

AU - Vincenti, Flavio

AU - de Andrés, Amado

AU - Becker, Thomas

AU - Choukroun, Gabriel

AU - Cole, Edward

AU - González-Posada, José M

AU - Kumar, Mysore A

AU - Moore, Richard

AU - Nadalin, Silvio

AU - Nashan, Björn

AU - Rostaing, Lionel

AU - Saito, Kazuhide

AU - Yoshimura, Norio

PY - 2006

Y1 - 2006

N2 - Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.

AB - Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.

M3 - SCORING: Zeitschriftenaufsatz

VL - 19

SP - 446

EP - 457

JO - TRANSPL INT

JF - TRANSPL INT

SN - 0934-0874

IS - 6

M1 - 6

ER -